ARVN - Arvinas, Inc.
About Arvinas, Inc. (https://www.arvinas.com)
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Noah Berkowitz | Chief Medical Officer | 1964 | $834,887 USD |
| Andrew Saik | Chief Financial Officer & Treasurer | 1969 | $819,563 USD |
| Angela Cacace | Chief Scientific Officer | 1968 | $758,163 USD |
| Randy Teel | CEO, President & Director | 1980 | $711,098 USD |
| Alexander A. Santini | Chief Commercial Officer | 1959 | – |
| David Loomis | Vice President & Chief Accounting Officer | 1974 | – |
| Jared Freedberg | General Counsel & Corporate Secretary | 1969 | – |
| Jeff Boyle | Vice President of Investor Relations | – | – |
| Kelly Page | Senior Vice President & Global Head of Oncology Strategy and Program Leadership | – | – |
| Lisa Sinclair | Senior Vice President of Corporate Operations | – | – |
| Paul McInulty | Senior Vice President of Regulatory Affairs | – | – |
| Steve Weiss | Senior Vice President & Chief Human Resources Officer | 1970 | – |